Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and six months ended June 30, 2014, and provided an update of recent corporate developments.
“We’ve made tremendous progress in advancing our eteplirsen clinical trials and are ready to begin our confirmatory ambulatory study this month, the first of three new studies with eteplirsen,” said President and Chief Executive Office Chris Garabedian.
Help employers find you! Check out all the jobs and post your resume.
